A study of comorbidities in myasthenia gravis
- 30 Downloads
Management of myasthenia gravis (MG) in the presence of comorbidities may be difficult. We report the effect of comorbidities in the outcome of MG. The patients with MG during 1991–2016 were included and evaluated including their demographic variables, clinical findings, Myasthenia Gravis Foundation of America (MGFA) score. The patients were categorized into early onset (≤ 40 years) and late onset (> 40 years) MG. The comorbidities (autoimmune and miscellaneous) and iatrogenic complications were compared between early and late onset, and in good and poor outcome groups. Out of 81 patients with MG, 48 patients had early and 33 late onset. In 71 (88%) patients, comorbidities were present and were autoimmune in 8 (10%) and miscellaneous in all the patients (88%). Iatrogenic complications were present in 54 (67%) patients. Thymectomy was done in 19 patients; 16 had thymoma and 3 thymic hyperplasia. Myasthenic crisis occurred in 28 patients; 5 (18%) had autoimmune and all had miscellaneous comorbidities. The patients with poor outcome had ≥ 2 comorbidities, myasthenic crisis, leukocytosis, elevated serum bilirubin and creatinine, and increased number of hospital admissions (P < 0.05). Myasthenia gravis is associated with comorbidities in majority of patients especially in late onset group, and more than two comorbidities are related to poor outcome.
KeywordsMyasthenia gravis Comorbidity Outcome Autoimmune Iatrogenic Drug induced Myasthenic crisis
Myasthenia Gravis Foundation of America
Muscle specific kinase
Lipoprotein-related protein 4
We thank Mr. Shakti Kumar for secretarial help.
UKM: Writing and drafting of manuscript. JK: Writing and drafting of manuscript. VKS: Data collection and analysis of data. SK: Data collection, analysis of data and statistical analysis.
Compliance with ethical standards
This study was approved by Institutional Ethics Committee, SGPGIMS, Lucknow INDIA. All the patients or care givers gave their written informed consent for research, which was conducted in accordance with the Helsinki Declaration.
Conflict of interest
The authors declare that the have no conflict of interest.
- 14.James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML et al (2014) Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC-8). JAMA 311:507–520CrossRefGoogle Scholar
- 15.American Diabetes Association (2016) Erratum. Classification and diagnosis of diabetes. Section 2. In Standards of Medical Care in Diabetes-2016. Diabetes Care 39(Suppl. 1):S13–S22. Diabetes Care. 39:1653 2016Google Scholar
- 16.Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK et al (2017) American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for the management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 23:479–497CrossRefGoogle Scholar
- 17.Clinical history and meeting the GOLD criteria for COPD (From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2014Google Scholar
- 20.Jallouli M, Saadoun D, Eymard B, Leroux G, Haroche J, Le Thi Huong D, De Gennes C, Chapelon C et al (2012) The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J Neurol 259:1290–1297CrossRefGoogle Scholar
- 24.Fink ME (1993) Treatment of the critically ill patient with myasthenia gravis. In: Ropper AH (ed) Neurological and neurosurgical intensive care, 3rd edn. Raven Press, New York, pp 351–362Google Scholar